Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies

Tissue Engineering - Part C: Methods

Volumn 17, Issue 5, 2011, Pages 549-556

  Zeilinger, Katrin ^a   Schreiter, Thomas ^a   Darnell, Malin ^b,c   Söderdahl, Therese ^b   Lübberstedt, Marc ^a   Dillner, Birgitta ^d   Knobeloch, Daniel ^a   Nüssler, Andreas K ^e   Gerlach, Jörg C ^f   Andersson, Tommy B ^b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOREACTORS; CELL CULTURE; CELLS; GLYCOPROTEINS; INNOVATION; LIVER; PROTEINS; THREE DIMENSIONAL; TISSUE;

BREAST CANCER RESISTANCE PROTEINS; CELL NUMBER; CYTOCHROME P450; DISTRIBUTION PATTERNS; HEPATIC FUNCTION; HOLLOW FIBER; HOLLOW FIBER BIOREACTOR; HUMAN LIVER; HUMAN LIVER CELLS; HUMAN LIVER TISSUES; IMMUNOHISTOCHEMICAL STUDIES; IN-VITRO; KINETIC STUDY; METABOLIC PARAMETERS; P-GLYCOPROTEIN; PHARMACOLOGICAL RESEARCH; SCALING DOWN; SUPPORT SYSTEMS;

BIOCONVERSION;

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; CYTOCHROME P450; GLYCOPROTEIN P; P GLYCOPROTEIN 2; P-GLYCOPROTEIN 2; TUMOR PROTEIN;

AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL LIVER; BIOREACTOR; CELL CULTURE; CULTURE TECHNIQUE; CYTOLOGY; ENZYMOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INSTRUMENTATION; LIVER; LIVER CELL; METABOLISM; METHODOLOGY; PERFUSION; PHYSIOLOGY; TIME; TISSUE ENGINEERING;

AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BIOREACTORS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER, ARTIFICIAL; NEOPLASM PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PERFUSION; TIME FACTORS; TISSUE ENGINEERING;

EID: 79955441221     PISSN: 19373384     EISSN: 19373392     Source Type: Journal    
DOI: 10.1089/ten.tec.2010.0580     Document Type: Article

References (25)

1. Gómez-Lechón, M.J., Castell, J.V., and Donato, M.T. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol 4, 837, 2008.
2. Tuschl, G., Lauer, B., and Mueller, S.O. Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. Expert Opin Drug Metab Toxicol 4, 855, 2008.
3. Adams, D.H., Ju, C., Ramaiah, S.K., Uetrecht, J., and Jaeschke, H. Mechanisms of immune-mediated liver injury. Toxicol Sci 115, 307, 2010.
4. McCuskey, R.S. Sinusoidal endothelial cells as an early target for hepatic toxicants. Clin Hemorheol Microcirc 34, 5, .2006.
5. Geubel, A.P., and Sempoux, C.L. Drug and toxin-induced bile duct disorders. Gastroenterol Hepatol 15, 1232, 2000.
6. Lavrijsen, K., van Houdt, J., van Dyck, D., Hendrickx, J., Bockx, M., Hurkmans, R., Meuldermans, W., Le Jeune, L., Lauwers, W., and Heykants, J. Comparative metabolism of flunarizine in rats, dogs and man: an in vitro study with subcellular liver fractions and isolated hepatocytes. Xenobiotica 22, 815, 1992.
7. Gebhardt, R., Hengstler, J.G., Mü ller, D., Glö ckner, R., Buenning, P., Laube, B., Schmelzer, E., Ullrich, M., Utesch, D., Hewitt, N., Ringel, M., Hilz, B.R., Bader, A., Langsch, A., Koose, T., Burger, H.J., Maas, J., and Oesch, F. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 35, 145, 2003.
8. Chan, C., Berthiaume, F., Nath, B.D., Tilles, A.W., Toner, M., and Yarmush, M.L. Hepatic tissue engineering for adjunct and temporary liver support: critical technologies. Liver Transpl 10, 1331, 2004.
9. Fiegel, H.C., Kaufmann, P.M., Bruns, H., Kluth, D., Horch, R.E., Vacanti, J.P., and Kneser, U. Hepatic tissue engineering: from transplantation to customized cell-based liver directed therapies from the laboratory. J Cell Mol Med 12, 56, .2008.
10. Gerlach, J.C., Mutig, K., Sauer, I.M., Schrade, P., Efimova, E., Mieder, T., Naumann, G., Grunwald, A., Pless, G., Mas, A., Bachmann, S., Neuhaus, P., and Zeilinger, K. Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors: a morphologic study. Transplantation 76, 781, 2003.
11. Zeilinger, K., Holland, G., Sauer, I.M., Efimova, E., Kardassis, D., Obermayer, N., Liu, M., Neuhaus, P., and Gerlach, J.C. Time course of primary liver cell reorganization in threedimensional high-density bioreactors for extracorporeal liver support: an immunohistochemical and ultrastructural study. Tissue Eng 10, 1113, 2004.
12. Schmelzer, E., Mutig, K., Schrade, P., Bachmann, S., Gerlach, J.C., and Zeilinger, K. Effect of human patient plasma ex vivo treatment on gene expression and progenitor cell activation of primary human liver cells in multi-compartment 3D perfusion bioreactors for extra-corporeal liver support. Biotech Bioeng 103, 817, 2009.
13. Pless, G., Steffen, I., Zeilinger, K., Sauer, I.M., Katenz, E., Kehr, D.C., Roth, S., Mieder, T., Schwartlander, R., Muller, C., Wegner, B., Hout, M.S., and Gerlach, J.C. Evaluation of primary human liver cells in bioreactor cultures for extracorporeal liver support on the basis of urea production. Artif Organs 30, 686, 2006.
14. Sauer, I.M., Zeilinger, K., Pless, G., Kardassis, D., Theruvath, T., Pascher, A., Goetz, M., Neuhaus, P., and Gerlach, J.C. Extracorporeal liver support based on primary human liver cells and albumin dialysis-treatment of a patient with primary graft non-function. J Hepatol 39, 649, 2003.
15. Gerlach, J., Brombacher, J., Kloppel, K., Schnoy, N., and Neuhaus, P. Comparison of four methods for mass hepatocyte isolation from pig and human livers. Transplantation 57, 1318, 1994.
16. Nussler, A.K., Nussler, N.C., Merk, V., Brulport, M., Schormann, W., Yao, P., and Hengstler, J.G. The holy grail of hepatocyte culturing and therapeutic use. In: Santin, M., ed. Strategies in Regenerative Medicine. New York: Springer, 2009, pp. 283-320.
17. Kanebratt, K.P., and Andersson, T.P. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36, 1444, 2008.
18. Guillouzo, A., Morel, F., Fardel, O., and Meunier, B. Use of human hepatocyte cultures for drug metabolism studies. Toxicology 82, 209, 1993.
19. Gómez-Lechó n, M.J., Donato, M.T., Castell, J.V., and Jover, R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4, 292, 2003.
20. Goyak, K.M.O., Johnson, M.C., Strom, S.C., and Omiecinski, C.J. Expression profiling of interindividual variability following xenobiotic exposures in primary human hepatocyte cultures. Toxicol Appl Pharmacol 231, 216, 2008.
21. LeCluyse, E.L. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13, 343, 2001.
22. Edling, Y., Sivertsson, L.K., Butura, A., Ingelman-Sundberg, M., and Ek, M. Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro 23, 1387, 2009.
23. Dash, A., Inman, W., Hoffmaster, K., Sevidal, S., Kelly, J., Obach, R.S., Griffith, L.G., and Tannenbaum, S.R. Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol 5, 1159, 2009.
24. Mottino, A.D., and Catania, V.A. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J Gastroenterol 14, 7068, 2008.
25. Vander Borght, S., Libbrecht, L., Katoonizadeh, A., van Pelt, J., Cassiman, D., Nevens, F., Van Lommel, A., Petersen, B.E., Fevery, J., Jansen, P.L., and Roskams, T.A. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J Histochem Cytochem 54, 1051, 2006.